Targeting mTOR and TF remodels the tumor microenvironment by reducing fibrin deposition (ameliorating hypercoagulability), altering collagen distribution (attenuating stromal fibrosis), decreasing CD31+, α-SMA+ vessel density, and diminishing CD206+, F4/80+ immunosuppressive M2 TAM infiltration. Here, MRC1 is linked to neoplasm.